Drug intelligence / Profile preview

EpiBone-CMF

Development stage: Unknown
Lead developer: EpiBone
Modality: Tissue Cells → Other Cell Types → Cell Therapies
Administration: Surgical Implantation

Overview

**EpiBone-CMF (EB-CMF)** is an autologous, living, anatomically precise bone graft engineered for craniomaxillofacial reconstruction, specifically targeting mandibular ramus continuity defects. Developed by EpiBone, Inc., it is manufactured from a patient's own adipose-derived mesenchymal stem cells seeded onto a scaffold and matured in a proprietary bioreactor to form functional bone tissue, eliminating the need for autologous bone harvesting and enabling a precision fit to the defect site. The product integrates with native tissue post-implantation, aiming to restore form and function while reducing surgical morbidity.[1][4][5][7]

Brand names: EB-CMF
Other names: EpiBone-Craniomaxillofacial

Beyond the preview

Go deeper on EpiBone-CMF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiBone-CMF.

Explore the full profile